about
Nanotechnology-based drug delivery systems for the treatment of Alzheimer's diseaseVinpocetine as a potent antiinflammatory agentAntinoceptive and Anti-inflammatory Activities of the Ethanolic Extract, Fractions and Flavones Isolated from Mimosa tenuiflora (Willd.) Poir (Leguminosae)Alternative medicine and Alzheimer diseaseVascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.Preparation and in vitro/in vivo evaluation of vinpocetine elementary osmotic pump system.Vinpocetine reduces carrageenan-induced inflammatory hyperalgesia in mice by inhibiting oxidative stress, cytokine production and NF-κB activation in the paw and spinal cord.Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cellsCognitive outcomes of prenatal antiepileptic drug exposure.Developmental effects of antiepileptic drugs and the need for improved regulations.Traditional Chinese medicine: a promising candidate for the treatment of Alzheimer's diseaseThe Relieving Effects of BrainPower Advanced, a Dietary Supplement, in Older Adults with Subjective Memory Complaints: A Randomized, Double-Blind, Placebo-Controlled TrialVinpocetine Inhibited the CpG Oligodeoxynucleotide-induced Immune Response in Plasmacytoid Dendritic Cells.Quantitative Determination of Vinpocetine in Dietary Supplements.Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions.Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.Treatment of vascular dementia. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases.The vincamine derivative vindeburnol provides benefit in a mouse model of multiple sclerosis: effects on the Locus coeruleus.Fixed Drug Eruption to Supplement Containing Ginkgo Biloba and Vinpocetine: A Case Report and Review of Related Cutaneous Side Effects.
P2860
Q26783306-FF0D51FE-B27B-4202-9D20-0D133F3B2C0FQ28283160-AC7C704C-8009-43E5-8709-4BB1B174AEE5Q28550593-91041A4C-35D1-4145-815B-447DEE09AD35Q28751860-D4072B49-776C-4F57-B1D4-C8F0498FA0A6Q33967781-A8D90550-86DC-4F96-9A8A-313798D885B0Q34960101-FF04E02F-F607-4BF9-8A7D-6C5A153FB560Q35590068-D22E764A-8D05-4CA9-A4FE-633C15DD8A58Q35705361-C2A43C3E-146A-4A25-A230-FA283A28C995Q35762249-EAB73E8D-EF72-4418-B4F3-B2E946E112C4Q36521267-AC68DDFC-7F15-4FE7-BE34-BDFE4AE8C5D7Q36689057-EF490B8A-E45A-46A8-82E4-AF847B5BB873Q36829198-8D4C464F-7601-4FDA-A18B-0ABE1E563CB0Q39102050-9899ADFC-D40B-43CF-93FD-A95649B1F4C8Q41888375-2D0DC8E0-0E1D-420D-B9A2-CF62D277E21FQ41903612-0BB3487A-FC8E-4D40-B802-F0ECDD23B771Q45305673-3B562B10-4014-41B1-A989-7C460FE8BF14Q47128027-7BE6DC57-98B1-42F1-AB9A-6BA1B69968DFQ47611446-F6DE38CE-9254-4227-99C6-F2265010053AQ48685237-AEC276EA-8F02-402D-BE8F-E2BE87469C82Q49360410-7E687393-DFF4-4031-96F9-6DFE18EBAE64
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Vinpocetine for cognitive impairment and dementia
@ast
Vinpocetine for cognitive impairment and dementia
@en
Vinpocetine for cognitive impairment and dementia
@en-gb
Vinpocetine for cognitive impairment and dementia
@nl
type
label
Vinpocetine for cognitive impairment and dementia
@ast
Vinpocetine for cognitive impairment and dementia
@en
Vinpocetine for cognitive impairment and dementia
@en-gb
Vinpocetine for cognitive impairment and dementia
@nl
prefLabel
Vinpocetine for cognitive impairment and dementia
@ast
Vinpocetine for cognitive impairment and dementia
@en
Vinpocetine for cognitive impairment and dementia
@en-gb
Vinpocetine for cognitive impairment and dementia
@nl
P2860
P1476
Vinpocetine for cognitive impairment and dementia
@en
P2093
Peter Whitehouse
Szabolcs Szatmári
P2860
P304
P356
10.1002/14651858.CD003119
P407
P577
2003-01-20T00:00:00Z